logo
Plus   Neg
Share
Email

Informa Says Events-related Business Hurt By COVID-19; Suspends Dividends

Informa plc (INFMF.PK,INF.L), an Exhibitions, Events, Business Intelligence and Academic Publishing Group, on Thursday issued an update on its trading as well as further details on its COVID-19 Action Plan.

The company announced further cost-reductions including pay cuts, the temporary suspension of dividends, discussions on a debt covenant waiver and the issue of additional new equity.

Informa said its approach through the period of the COVID-19 pandemic is to focus on the long-term strength and value of its Brands and customer relationships.

Regarding its trading, the company said the impact on Events-related businesses, about 65 percent of revenue, has intensified significantly since the initial disruption early in the first quarter in Mainland China, with no events of any scale scheduled to take place in April.

The company now expects the reduced level of activity to stretch through the second quarter and much of the third quarter, with a gradual and phased recovery from the third quarter into the final quarter of the year.

Further, subscriptions-related businesses, around 35 percent of revenue, have remained resilient and continue to grow consistently.

"Whilst the power of Informa's B2B events businesses continue to be evidenced by customer enquiries and re-bookings, it is now clear the path to the other side of COVID-19 will be more gradual and phased than initially anticipated," the company said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard. Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial. Shares of Moderna Inc. (MRNA) slipped over 5% on Thursday after a report claimed that the biotechnology company's late-stage trial for a coronavirus vaccine will be delayed. Moderna is developing mRNA-1273 in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). The...
RELATED NEWS
Follow RTT